Skip to main content Skip to secondary navigation

Docket #: S23-099

Massively Parallel Mixed Lymphocyte Reactions

Stanford researchers have developed technology enabling pooling and simultaneous testing of engineered T cells from multiple human donors. This invention increases scale and reduces costs for diagnostic, and pre-clinical development of engineered T cell therapies.

Engineered immune cell testing, particularly CAR-T cells, is costly and time-consuming. A major challenge is the inability to pool T cells from multiple donors due to mutual recognition as foreign cells. In this invention Stanford researchers have developed technology to be able to successfully pool and simultaneously test T cells from multiple human donors without adverse reactions between the T cells from different donors.

Stage of Development
In vitro

Applications

  • Cell therapy development
  • Cell therapy diagnostic

Advantages

  • Scaleable
  • Significantly cheaper and less resource intensive

Patent Status

Provisional patent application filed

Related Links

Similar Technologies

Explore similar technologies by keyword: